Skip to content
OpenCapital
Get started

Aquestive Therapeutics, Inc. AQST Liabilities, Sale of Future Royalties

Other financials

Income statement

See full
Revenue$14.4M+65.7%
Gross profit$11.0M+117%
Operating income-$4.2M+78.3%
Net income-$8.1M+64.9%
EPS (diluted)-$0.07+70.8%

Balance sheet

See full
Cash & equivalents$110.7M+61.3%
Total debt$64.4M+7.4%
Total equity-$34.1M+44.1%
Total assets$141.1M+38.0%

Cash flow

See full
Operating cash flow-$14.8M+36.7%
CapEx$52.0K-61.5%
Free cash flow-$14.9M+36.9%

Valuation

See full
Market cap$560.13M+73.5%
Enterprise value$513.76M+63.6%
P/S11.1×+5.2×

Profitability

See full
Gross margin63.5%-4.9pp
Operating margin-111.2%+96.3pp
Net margin-137.1%+80.7pp
FCF margin-88.2%-2.2pp

Returns & leverage

See full
Return on equity145.1%—
Debt / equity-1.9×—
Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept aqst:LiabilitiesSaleOfFutureRoyalties.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s liabilities, sale of future royalties.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s liabilities, sale of future royalties?
Aquestive Therapeutics, Inc. (AQST) reported liabilities, sale of future royalties of $63.08M in Q1 2026.
How has Aquestive Therapeutics, Inc.'s liabilities, sale of future royalties changed year-over-year?
Aquestive Therapeutics, Inc.'s liabilities, sale of future royalties decreased by 1.1% year-over-year, from $63.78M to $63.08M.
What is the long-term trend for Aquestive Therapeutics, Inc.'s liabilities, sale of future royalties?
Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s liabilities, sale of future royalties has grown at a 5.2% compound annual growth rate (CAGR), from $48.97M to $63.02M.